Next Article in Journal
The Impact and Effectiveness of Weight Loss on Kidney Transplant Outcomes: A Narrative Review
Previous Article in Journal
Determinants of Nutritional Risk among Community-Dwelling Older Adults with Social Support
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Nutrients
Volume 15
Issue 11
10.3390/nu15112507
nutrients-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Physalis alkekengi L. Calyx Extract Alleviates Glycolipid Metabolic Disturbance and Inflammation by Modulating Gut Microbiota, Fecal Metabolites, and Glycolipid Metabolism Gene Expression in Obese Mice

by
Lin Li
1,
Xiaolong Wang
1,
Ying Zhou
1,
Na Yan
2,
Han Gao
1,
Xiaojie Sun
1 and
Chunjing Zhang
1,*
1
Department of Medical Technology, Qiqihar Medical University, Qiqihar 161006, China
2
Department of Basic Medical Science, Qiqihar Medical University, Qiqihar 161006, China
*
Author to whom correspondence should be addressed.
Nutrients 2023, 15(11), 2507; https://doi.org/10.3390/nu15112507
Submission received: 6 May 2023 / Revised: 25 May 2023 / Accepted: 26 May 2023 / Published: 28 May 2023
(This article belongs to the Topic Gut Microbiota in Human Health)
Browse Figures
Review Reports Versions Notes

Abstract

:
Physalis alkekengi L. calyx (PC) extract can relieve insulin resistance and has glycemic and anti-inflammatory effects; however, the potential mechanisms related to gut microbiota and metabolites remain elusive. This study aimed to understand how PC regulates gut microbiota and metabolites to exert anti-obesogenic effects and relieve insulin resistance. In this study, a high-fat high-fructose (HFHF)-diet-induced obesity C57BL/6J male mice model with glycolipid metabolism dysfunction was established, which was supplemented with the aqueous extract of PC daily for 10 weeks. The results showed that the PC supplementation could effectively cure the abnormal lipid metabolism and maintain glucose metabolism homeostasis by regulating the expression of adipose metabolic genes and glucose metabolism genes in the liver, thereby effectively alleviating the inflammatory response. PC treatment also increased the contents of fecal short-chain fatty acids (SCFAs), especially butyric acid. PC extract could restore the HFHF-disrupted diversity of gut microbiota by significantly increasing the relative abundance of Lactobacillus and decreasing those of Romboutsia, Candidatus_Saccharimonas, and Clostridium_sensu_stricto_1. The negative effects of the HFHF diet were ameliorated by PC by regulating multiple metabolic pathways, such as lipid metabolism (linoleic acid metabolism, alpha-linolenic acid metabolism, and sphingolipid metabolism) and amino acid metabolism (histidine and tryptophan metabolism). Correlation analysis showed that among the obesity parameters, gut microbiota and metabolites are directly and closely related. To sum up, this study suggested that PC treatment exhibited therapeutic effects by regulating the gut microbiota, fecal metabolites, and gene expression in the liver to improve glucose metabolism, modulate adiposity, and reduce inflammation.

Graphical Abstract

1. Introduction

For the past few years, the dietary structure of people has changed significantly with the improvement of the economic level to a diet rich in processed foods and beverages that are high in energy, fat, and sugar. The changes in dietary structure have resulted in the rapid growth of the global overweight and obesity populations [1,2]. The long-term intake of a high-fat and high-fructose diet (HFHF) leads to an excessive intake of high-energy-density fat, which causes the imbalance of energy metabolism and induces the disorder of lipid and sugar metabolism [3], thereby leading to obesity and other related chronic metabolic diseases, such as metabolic syndrome; non-alcoholic fatty liver, cardiovascular, and cerebrovascular diseases; and diabetes [4,5,6].
The liver, as the main organ for lipid metabolism, is an important target organ for obesity. The intake of an HFHF diet increases the burden of liver glycolipid metabolism, causes lipid peroxidation, and affects the normal physiological function of liver and belly cells [7,8]. Moreover, the long-term intake of the HFHF diet can also increase the total liver weight and liver lipid contents, mainly including total cholesterol (TC), triglyceride (TG), and free fatty acid (FFA) contents [9]. This results in the excessive accumulation of fats in the liver and leads to glucose metabolic disorder due to high plasma glucose and insulin levels, resulting in insulin resistance (IR) [10,11].
In recent years, the gut microbiota has attracted the attention of researchers working on metabolic diseases worldwide [12]. The regulation of the gut microbiota can efficaciously improve and prevent the occurrence and development of obesity, IR, and chronic inflammation [13]. Some basic research results show that obesity can increase intestinal permeability, the relative lack of diversity in the gut microbiota [14], a decrease in Bacteroidetes, and an increase in the number of Firmicutes in proportion to a healthy gut microbiota [15,16]. Short-chain fatty acids (SCFAs) are the most abundant microbial metabolite complex derived from carbohydrates and plant polysaccharides in the gut, which can provide energy for microorganisms and the human body [17,18]. Some prebiotics have been used in clinical trials to regulate intestinal microbiota composition and the content of SCFAs in order to reduce obesity and regulate the blood lipid level of the subjects and achieved a good effect [19,20].
Oral administration is the most important mode to administer traditional Chinese medicine (TCM). After entering the intestine, TCMs are in close contact with intestinal microbiota and mainly manifested by regulating the structure of the gut microbiota or the metabolism of active components in TCM, which is an important mechanism for the pharmacological effects of TCM. Huang-Lian-Jie-Du-Decoction (HLJDD) could ameliorate hyperglycemia and restore the dysbiosis of gut microbiota [21]. Corn silk extract also had a decreasing lipoglycemic effect by modulating the fecal metabolites and gut microbiota among hypercholesterolemic mice, which were induced by a high-fat diet [22]. Qingzhuan tea extract supplementation in the diet can improve the symptoms of metabolic syndrome in mice induced by a high-fat diet by regulating the gut microbial structure [20]. All these studies showed the good preventive effect of TCM extracts on ameliorating hyperglycemia and hyperlipemia by regulating the gut microbial structure or metabolism.
Physalis alkekengi L. is commonly known as brocade lantern, red girl, etc., and is a perennial plant of the Solanaceae family of herbs. It is a kind of herb resource used both as food and medicine, and diabetes patients often use its calyx as tea to regulate blood glucose in China [23]. Moreover, both its resting calyx and the fruit within are edible, and their extracts have been investigated for their anti-inflammatory glycemic effects, insulin resistance relief effects, and antioxidant effects [24,25,26,27]. It has been confirmed that the substances exerting these pharmacological effects are polysaccharides, sterols, and flavones in fruit and calyx [28]. Although the medicinal value of calyx extract in regulating glycolipid metabolism has been reported, the specific mechanism of lowering glycolipid has not been systematically studied. Research on the effects of supplement PC extract in the diet on the structure of gut microbiota and related metabolite profiles is still scant.
The present study aimed to investigate the effects of PC extract on regulating gene expression in glycolipid metabolism as well as the gut microbiota composition and metabolites in feces in HFHF-diet-fed mice. This study might enhance the understanding of how PC exerts anti-obesogenic and insulin-resistance-relieving effects by modulating gut microbiota, fecal metabolites, and glycolipid metabolism gene expression.

2. Materials and Methods

2.1. Materials and Reagents

For the preparation of the PC extract, the calyx of the P. alkekengi was naturally dried and crushed through a 2 mm sieve followed by extraction with distilled water (90 °C) for 15 min (1:15 w/v), gently stirring, and extraction twice [29]. The two water extracts were then mixed. In order to facilitate storage, the extracted mixture was centrifuged for 5 min at 5000 rpm, and the supernatant was taken and concentrated under reduced pressure for 1 h at 65 °C. Finally, the powder obtained by vacuum freeze-drying was stored at −20 °C for further use. The contents of polysaccharides, total phenols, and total flavonoids in the water extract were 45.11 mg/g, 1.15 mg/g, and 1.72 mg/g, respectively. The polysaccharides estimation was performed using the phenol-sulfuric acid method, total flavonoids analysis by the AlCl3 spectrophotometric method, and total phenols measurement using the Folin–Ciocalteu method. The metabolites of the PC extract were analyzed by Beijing BioMarker Technology Co., Ltd. (Beijing, China). In total, we detected 1381 metabolites from freeze-drying the extract, and most of them belong to fatty acyls, Carboxylic acids and derivatives, Organooxygen compounds, Prenol lipids and Steroids, and steroid derivatives (Supplementary Figure S1).

2.2. Animals and Experimental Design

Six-week-old male C57BL/6 mice, weighing 20.0 ± 1.0 g, were purchased from Liaoning Changsheng biotechnology Co., Ltd. (Liaoning, China). All the animal experiments and procedures were approved by the Ethics Committee of the Laboratory Animal Center, Qiqihar Medical University, Qiqihar, China (approval no. QMU-AECC-2021-172). All mice were fed by the experimental animal center of Qiqihar Medical University (SYXK (HEI) 2016-001). After one-week acclimatization, a total of 28 mice were divided into four groups randomly (n = 7 per group): in the NC group, the mice were fed with a standard diet, which contain 10% fat by energy; in the HFHF group, the mice were fed with high-fat feed (60% fat by energy) and a high-fructose diet (drinking water supplemented with 30% fructose); and in the PCL and PCH groups, the mice were fed with a high-fat high-fructose diet and administered with PC 300 mg/kg/day (PCL group) and 600 mg/kg/day (PCH group) by gavage every day (the experimental protocol is detailed in Figure 1A). The experiment lasted for 10 weeks, and the animal weights and food intakes were recorded weekly during the study. At the end of the study, the fresh fecal samples were collected and stored at −80 °C for subsequent analyses of gut microbiota and metabolites as well as SCFAs. After fasting overnight, the mice were sacrificed, and their liver, kidney, epididymis, and subcutaneous fatty tissues were collected, weighed, and stored at −80 °C. The mice serum samples were obtained by centrifugation (1200× g, 15 min) and stored at −80 °C for further use.

2.3. Biochemical Analysis

The serum triglyceride (TC), total cholesterol (TG), non-esterified fatty acid (NEFA), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) levels as well as enzymes levels, including alanine aminotransferase (ALT) and aspartate aminotransferase (AST), were measured using an auto-biochemistry analyzer (Hitachi Ltd., Tokyo, Japan). The levels of inflammatory factor tumor necrosis factor α (TNF-a), interleukin-6 (IL-6), interleukin-1β (IL-1β), monocyte chemotactic protein-1 (MCP-1), lipopolysaccharide (LPS), and serum fasting insulin (FINS) were detected by using an ELISA kit (Nanjing Jiancheng Institute of Bioengineering, Nanjing, China).
The mice were fasted overnight for 12 h prior to the oral glucose tolerance test (OGTT). A 2 g/kg glucose solution was intragastrically administered, and the tail venous blood was taken after 0, 30, 60, and 120 min of the intragastric administration, using a blood glucose meter (Jiangsu Yuyue Medical Equipment & Supply Co., Ltd., Danyang, China). A line graph was drawn using the obtained blood glucose concentration as the vertical coordinate and the corresponding measurement time as the horizontal coordinate, and the area under the curve (AUC) was calculated using the trapezoid rule [30]. The homeostasis model assessment parameter of insulin resistance (HOMA-IR) was calculated using the following formula: HOMA-IR = FINS (mU/L) × FBG (mmol/L)/22.5, HOMA insulin sensitivity (HOMA-IS) index = 1/(FBG × FINS).

2.4. Histopathological Analysis

The mice liver and adipose tissues were dissected, extracted, and then fixed with 4% paraformaldehyde. After fixation, the tissue sections were stained with hematoxylin and eosin (H&E), and the structure of liver and adipose tissues was observed and analyzed under an optical microscope [31].

2.5. Quantitative Real-Time PCR

Total RNA was extracted from the liver tissues using a Biozol reagent (Invitrogen, Carlsbad, CA, USA), as described previously [32]. The concentration of extracted RNA was determined using a NanoDrop spectrophotometer (BioTeke, Beijing, China). The RNA was reverse-transcribed into cDNA using a reverse transcriptase kit (TransGen Biotech, Beijing, China) following the manufacturer’s instructions. The relative expression levels of genes involved in glycolipid metabolism as well as inflammatory factors (IL-6, IL-β, and TNF-a) and MCP-1 in the liver were measured. The PCR amplification was performed with Trans Start® Top Green qPCR SuperMix (TransGen Biotech, Beijing, China) using the ABI 7500 Fast Dx PCR instrument (Applied Biosystems, Foster City, CA, USA). The relative expression levels of the quantitative genes were identified using the 2−ΔΔCt method, with the β-actin set as the reference gene and the NC group as the control. The primer sequences are listed in Supplementary Table S1.

2.6. Analysis of Short-Chain Fatty Acids

The determination of SCFAs (acetic acid, propionic acid, butyric acid, isobutyric acid, and valeric acid) was performed using gas chromatography (GC) by Shanghai Personalbio Technology Co., Ltd. (Shanghai, China). First, the contents of fecal samples were collected, samples were thawed on ice, and 30 mg of the sample was placed in a 2 mL glass centrifuge tube. Then, 900 μL 0.5% phosphoric acid was added and resuspended, and the mixture was shaken for 2 min. After centrifugation at 14,000× g for 10 min, 800 μL of the supernatant was taken, and the same amount of ethyl acetate was added for extraction, shaken, mixed for 22 min, and centrifuged at 14,000× g for 10 min. The upper organic phase of 600 μL was mixed with 4-methylvaleric acid (final concentration 500 μM) as an internal standard and then added into the injection bottle for GC-MS detection. The injection volume was 1 μL, and the split ratio was 10:1. MSD ChemStation software was used to extract chromatographic peak areas and retention times. The standard curve was drawn to calculate the SCFAs in the sample [32].

2.7. Analysis of Gut Microbiota

Total genomic DNA was extracted from the fecal samples using the MOBIO PowerSoil® DNA Isolation Kit (MOBIO Laboratories, Inc., Carlsbad, CA, USA), followed by the amplification and sequencing of hypervariable V3-V4 region in the 16S rRNA gene using the Illumina Novaseq 6000 platform by Beijing Bio Marker Technology Co., Ltd. (Beijing, China). The detailed analysis methods are described in a previous study [32]. USEARCH software was used for the clustering of sequence reads with a 97.0% similarity level, and OTUs were obtained [33]. Then, the composition of gut microbiota in each sample at each level (phylum, class, order, family, genus, and species) was determined, and the species abundances at different classification levels were identified using the QIIME software. The α and β diversities were analyzed to reveal the diversity and structure of gut microbiota. β diversity analyses included non-metric multidimensional scaling (NMDS) and principal coordinate analysis (PCoA) based on the Bray–Curtis algorithm; ANOSIM analysis was used to test for significant differences in the clusters among the groups [34]. LEfSe (linear discriminant analysis (LDA) effect size) was used to find biomarkers with statistical differences between different groups.

2.8. Untargeted Metabolomics Analysis

Fecal metabolome analysis was performed by Beijing BioMarker Technology Co., Ltd. (Beijing, China). The analysis mainly included thawing, grinding, extraction, vacuum drying of fecal samples, etc. The detailed steps are following the reference and our previous study [35,36] and in Supplementary Materials.

2.9. Statistical Analysis

Among different groups, statistical significance was set at p < 0.05 and determined with one-way ANOVA by using the Tukey–Kramer post hoc test. The results were expressed as mean ± SD. The correlations found among variables were identified by Pearson’s product-moment correlation coefficient. Statistical tests were performed using R software (Version 4.2.1) for Windows.

3. Results

3.1. PC Prevented HFHF-Induced Obesity in Mice

During the experimental period (Figure 1A), the mice groups showed changes in their weights after 10 weeks (Figure 1B). The initial weights were similar among the four groups. The final body weights of mice in the NC, HFHF, PCL, and PCH groups were 30.58 ± 1.16 g, 40.92 ± 1.71 g, 37.88 ± 1.11 g, and 34.64 ± 1.33 g, respectively. As compared to the NC, the mice weight increased more rapidly in the HFHF group, and the weight of the mice in the PCL and PCH groups decreased significantly by 7.43% and 15.35%, respectively, as compared to those in the HFHF group (Figure 1C, p < 0.05). There were no differences in the daily food intake by mice among the four groups, showing that the suppressed body weight effect of PC did not come from the reduction in food consumption (Figure 1D, p > 0.05). Consistently, the PC administration reduced the weights of liver and subcutaneous tissues as compared to those in the HFHF group. Moreover, the high-dose administration of PC also significantly reduced the weight of epididymal tissue (Figure 1E, p < 0.01); however, the weight of kidneys did not change among the four groups (p > 0.05). H&E staining showed that the PC treatment significantly reduced the cell diameter of adipocytes (Figure 1F).
Nutrients 15 02507 g001 550
Figure 1. (A) The experimental scheme, n = 7 in each group; and effects of PC supplementation on the (B) body weight. * p < 0.05, PCH compared with HFHF; # p < 0.05, PCL compared with HFHF. (C) Body weight gain, (D) food intake, (E) organ weights, and (F) histology analysis of adipose tissue. The length of the black line in the figure represents 50 μm. Data are expressed as means ± SD (n = 7). * represents p < 0.05, ** represents p < 0.01, *** represents p < 0.001, and ns represents not significant.
Figure 1. (A) The experimental scheme, n = 7 in each group; and effects of PC supplementation on the (B) body weight. * p < 0.05, PCH compared with HFHF; # p < 0.05, PCL compared with HFHF. (C) Body weight gain, (D) food intake, (E) organ weights, and (F) histology analysis of adipose tissue. The length of the black line in the figure represents 50 μm. Data are expressed as means ± SD (n = 7). * represents p < 0.05, ** represents p < 0.01, *** represents p < 0.001, and ns represents not significant.
Nutrients 15 02507 g001

3.2. PC Improved Glucose Homeostasis and Alleviated HFHF-Induced Insulin Resistance

After the 10-week experimental period, OGTT was used to evaluate glucose homeostasis (Figure 2). The results indicated that the blood glucose level was higher in the HFHF group as compared to that in the NC group, while PC supplementation significantly decreased the blood glucose level in HFHF-fed mice (p < 0.05). The OGTT showed that the oral glucose tolerance of the HFHF group mice was lower than that of the NC group mice, with a significantly increased AUC value (p < 0.01). Consistently, the PC administration significantly prevented the HFHF-induced impairment of OGTT. Obesity, caused by a high-fat and high-fructose diet, is also closely related to insulin resistance. As compared to the NC group, the FINS level increased significantly in the HFHF group, which was indicated by a significant increase in the HOMA-IR index and a significant decrease in the HOMA-IS index. The PC supplementation for 10 weeks significantly prevented these adverse changes, leading to a decrease in the FINS level and HOMA-IR index and a significant increase in HOMA-IS index (p < 0.05) in the PCL and PCH groups as compared to those in the HFHF group.

3.3. PC Attenuated the HFHF-Induced Dyslipidemia

Obesity is usually accompanied by fat accumulation and elevated blood lipids. As shown in Figure 3A–E, the serum levels of TG, TC, NEFA, and LDL-C were significantly increased in HFHF mice as compared to those in the NC group. The PC supplementation reversed these indices. Surprisingly, there was no significant difference in the serum levels of HDL-C in mice among the four groups. Additionally, the HFHF-fed mice were characterized by higher levels of TG, TC, and NEFA in the liver, which were also significantly reversed by PC supplementation (Figure 3F–H). These data suggested that the PC could protect mice against hyperlipidemia induced by HFHF.
As compared to the NC group (Figure 3I,J), the serum AST and ALT levels increased significantly in the HFHF group (p < 0.01). The high-dose PC supplements effectively prevented HFHF-induced liver damage by ameliorating the serum AST and ALT levels as compared to those in the HFHF group (p < 0.01); however, we did not observe significant changes in ALT levels between HFHF and PCL groups. H&E staining also showed that the PC treatment reduced the ballooning degeneration in the liver significantly (Figure 3K). These results suggested that PC supplementation could effectively suppress HFHF-induced liver lipotoxicity.

3.4. PC Modified the Expression Profiles of Genes Involved in Glycolipid Metabolism in Livers

In order to further explore the effects of PC on glycolipid metabolism in the liver were investigated. As compared to NC, the expression levels of lipid synthesis genes (Figure 4A), including FAS, ACC1, SCD1, SREBP-1c, and ChREBPα increased significantly in the HFHF group; these increased expression levels were significantly downregulated by PCH treatment as compared to those in the HFHF group (p < 0.05). The expression levels of fatty acid oxidation genes, such as Pparα, Cpt1α, and Acox1 significantly increased in the PCH group as compared to those in the HFHF group (Figure 4B, p < 0.05).
In order to reveal the mechanism of lowering the blood glucose level and improving glucose homeostasis by PC, the expression levels of two gluconeogenesis-related genes (G6Pase and PEPCK) in the liver were determined (Figure 4C). The expression levels of G6Pase and PEPCK in the mice liver in the HFHF group were significantly upregulated compared with the NC group. The PC treatment significantly downregulated the expression of these two genes.

3.5. PC Inhibited the HFHF-Induced Secretion of Proinflammatory Cytokines

To evaluate the anti-inflammation effects of PC, the serum levels of proinflammatory cytokines, including TNF-α, IL-1β, IL-6, MCP-1, and LPS, were examined in mice. As shown in Figure 5A,B, the serum levels of TNF-α, IL-1β, and MCP-1 increased significantly in the HFHF group as compared to the NC group (p < 0.05), while that of IL-6 showed no significant changes (p > 0.05). Under the HFHF diet, the PC supplement could significantly reduce the serum levels of TNF-α, IL-1β, and MCP-1 as compared to HFHF-induced mice, and the effects of the PCH group were better than those of the PCL group. Moreover, HFHF significantly increased the mRNA expression levels of TNF-α, IL-1β, IL-6, and MCP-1 in liver tissues as compared to those in the NC group (Figure 5C). The PCH treatment significantly reduced the expression levels of these proinflammatory cytokines (TNF-α, IL-1β, and MCP-1) in the liver as compared to those in the HFHF group. There were no significant differences in the expression levels of TNF-α and IL-6 in mice liver between PCL and HFHF groups (p > 0.05). The PC supplementation significantly reduced the serum level of LPS in HFD-induced mice in a dose-dependent manner (p < 0.01, Figure 5D).

3.6. PC Altered the Fecal SCFAs Composition

As shown in Figure 6, the concentrations of SCFAs in feces were determined. In the HFHF group, the contents of acetate, butyrate, and total SCFAs decreased by 17.17%, 44.41%, and 16.38%, respectively, as compared to those in the NC group; this decrease was reversed by the PCH supplementation. Moreover, the butyrate acid content increased significantly in the PCL group as compared to that in the HFHF group. This suggests that PC supplementation could increase the butyrate content. However, there were no differences in the contents of propionate, valeric acid, and isobutyric in the four groups.

3.7. PC Modulated Gut Microbiota Composition at Different Taxonomic Levels

The V3-V4 hypervariable region of the 16S rRNA gene was sequenced on an Illumina MiSeq platform to assess the effects of PC on the gut microbiota composition. A total of 1,650,700 clean reads were detected after quality filtering in the 28 samples (n = 7 per group) and obtained 58,954 clean reads per sample on average. The Chao1, Shannon, and Simpson indices were measured to evaluate the effect of PC on gut microbiota community richness and microbial evenness (Figure 7A). As compared to the NC group, the Chao1 index and Simpson index decreased significantly in the HFHF group, and the Shannon index decreased with no statistical significance (p > 0.05); this decrease was reversed by PC supplementation in the PCH group (p < 0.05). This indicated that PC could restore the HFHF-induced low diversity of gut microbiota.
Beta diversity was assessed using PCoA and NMDS on the Bray–Curtis algorithm to show the effects of PC on the community composition of gut microbiota (Figure 7B,C). PCoA realizes the classification of multiple samples and shows the differences in species diversity among different samples. The closer the samples are on the coordinate map, the greater the similarity between them. Principal coordinates were used for the three-dimensional expansion (Figure 7B), where the contribution rates of PC1, PC2, and PC3 were 32.47%, 15.05%, and 8.79%, respectively. The samples in the NC and PCH groups were mainly concentrated in the plane formed by PC1 and PC3, while the samples in the HFHF and PCL groups were mainly concentrated in the PC2, indicating that PCH could partly restore the health status of HFHF-disrupted gut microbiota. The NMDS of the microbial composition also revealed that the PCH treatment groups had different microbial community structures as compared to those in the HFHF groups (Figure 7C).
To further explore the effects of PC on the composition of gut microbiota, we identified the microbiota relative abundance at the phylum, family, and genus levels to demonstrate the essential changes induced by HFHF and PC. At the phylum level (Figure 7D), Firmicutes, Bacteroidetes, Actinobacteria, Patescibacteria, Proteobacteria, and Desulfobacterota were the top six most abundant phyla and formed 97% of total gut bacteria in the four groups. The results showed that the gut microbiota in the HFHF group consists of much more Firmicute with less Bacteroidetes as compared to those in the NC group, leading to an increase in the Firmicute/Bacteroidetes ratio (F/B ratio); however, the high-dose PC supplementation reversed these changes (p < 0.05, Figure 7E–G). The high-does PC treatment also prevented an HFHF-induced increase in the Firmicute/Bacteroidetes ratio (F/B ratio) (Figure 7G), which is a hallmark of obesity and a common indicator for the imbalance of gut microbiota. Moreover, as compared to the NC group (Figure 7H), the relative abundance of Patescibacteria was much higher in the HFHF group and significantly lower in the PCL and PCH groups (Figure 7H). At the family level, the top three abundant families were Bacilli, Clostridia, and Bacteroidia in the four groups. The relative abundances of these three bacterial families significantly changed after PC treatment as compared to those in the HFHF group (Supplementary Figure S2). PCH could effectively reverse the HFHF-induced decrease in the relative abundance of Bacteroidetes; similarly, PCL treatment could also increase the relative abundance of Bacteroidetes, but the difference was not significant. Both the PCL and PCH treatments decreased the relative abundance of Saccharimonadia as compared to that in the HFHF group. PCH also significantly decreased the relative abundance of Clostridia. These results indicated that low-dose PC treatment had little effect on the composition of gut microbiota.
Furthermore, the top 15 abundant bacterial genera are shown in Figure 8A,B. The HFHF feeding increased the relative abundances of Ligilactobacillus, Romboutsia, Candidatus_Saccharimonas, Clostridium_sensu_stricto_1, and Monoglobus as compared with the NC group. This increase was reversed by the PCH treatment (p < 0.05). As compared to the HFHF group, the genus unclassified_Muribaculaceae was more enriched in the PCH groups, and the genus Lactobacillus was more enriched in the NC and PCH groups. LEfSe analysis showed PCH group enrichment in unclassified_Muribaculaceae, whereas the HFHF group was enriched in Clostridium_sensu_stricto_1 (LDA scores > 4.5, Figure 8C).
The altered glycolipid metabolism and inflammation index might reflect the functions of the gut microbiota. Therefore, the functional correlations were explored between significantly differential bacteria at the genus level and obesity parameters associated with glucolipid metabolism and inflammation (Figure 8D). The results showed that Romboutsia, Candidatus_Saccharimonas, Clostridium_sensu_stricto_1, and Monoglobus were significantly positively correlated with the parameters of glycolipid metabolism and inflammation and negatively correlated with acetic acid (AA) and butyric acid (BA), which belonged to SCFAs. Lactobacillus showed a negative correlation with the parameters of glycolipid metabolism and inflammation except for FINS and serum TG as well as a significant positive correlation with BA.

3.8. PC Altered the Gut Metabolic Profile in Mice

Untargeted fecal metabolomic analysis based on the LC-QTOF platform and qualitative and quantitative metabolomic analysis were performed on 28 samples. A total of 10,230 peaks were detected in the positive ionization mode, among which 2417 metabolites were noted, and 10,291 peaks were detected in the negative ionization mode, among which 2025 metabolites were noted. To investigate the fecal metabolite differences among NC, HFHF, PCL, and PCH groups in mice, PCA and OPLS-DA were performed (Figure 9). The PCA results showed that the NC group was clearly distinguished from the other three groups for both positive (POS) and negative (NEG) modes (Figure 9A). To further reflect the differences between treatments (Figure 8B,C), the OPLS-DA results of the permutation test validated the model and revealed that fecal metabolites significantly differed between NC and HFHF mice in both POS and NEG modes (Figure 9B), and the results demonstrated that the fecal metabolites were altered in the PCH group compared to the HFHF mice (Figure 9C). It also showed different changes between PCL and HFHF groups (Supplementary Figure S3). The result suggests that PC supplementation could regulate the metabolic profiles of the mice.
The volcano plot was applied to determine the overall trend of differences in metabolite contents between the two groups. The statistical significance of the differences and metabolites with VIP > 1, p < 0.05, and fold change (FC) ≥ 2 was significantly altered by PC (Figure 10A–D). As compared to the NC group, in the positive ionization mode, 299 metabolites were upregulated and 162 metabolites were downregulated in the HFHF group, while in the negative ionization mode, 88 metabolites were upregulated and 186 metabolites were downregulated. In the PCH group, 337 metabolites were upregulated and 296 metabolites were downregulated in the positive ionization mode, while in the negative ionization mode, 74 metabolites were upregulated and 256 metabolites were downregulated as compared to the HFHF group. There were also significant differences in metabolites between the PCL and HFHF groups (Supplementary Figure S4). Based on the volcanic map results, hierarchical clustering heat maps are further drawn for the screened differential metabolites (Figure 10E,F).
The Human Metabolome Database (HMDB) was used to annotate and classify the differential metabolites. (Figure 10G, Supplementary Figure S5A). The results indicated that compared to the NC group, most of the HFHF-induced differential metabolites belonged to lipids and lipid-like molecules, organic acids and derivatives, organoheterocyclic compounds, benzenoids, and organic nitrogen compounds. The high-dose PC supplementation regulated most of these metabolites, including lipids and lipid-like molecules, organoheterocyclic compounds, organic acids and derivatives, benzenoids, phenylpropanoids and polyketides, and organic oxygen compounds. Most subclasses belonged to gycerophosphates glycerophosphoethanolamines, amino acids, peptides and their analogs, lineolic acids and derivatives, bile acids, alcohols and derivatives, fatty acids and conjugates, diradvloivcerols, carbohydrates, carbohvdratecoiuoates, etc. (Supplementary Figure S5B–D). In order to further explore the metabolic pathways associated with these changed metabolites by PC supplementation, the KEGG database was used for the pathway enrichment analysis. The cluster profiler hypergeometric test was used to enrich and analyze the annotation results of differential metabolites, and a bubble map was drawn. The redder the dot color, the more significant the enrichment, and the dot size represents the number of differentiated enriched metabolites. The top 20 significant pathways are shown in Figure 10H and Supplementary Figure S6. The top 20 metabolic pathways, which were regulated after PCH treatment, are also shown. The metabolic pathways with the highest enrichment mainly included linoleic acid metabolism, one carbon pool by folate, alpha-linolenic acid metabolism, sphingolipid metabolism, histidine metabolism, folate biosynthesis, glycerophospholipid metabolism, tryptophan metabolism, purine metabolism, and steroid hormone biosynthesis. This showed that these pathways were mainly involved in lipid and amino acid metabolism pathways. These results suggested that the PC supplementation could alter the fecal metabolic profile of glycolipid and amino acid metabolism in mice.
Gut microbiota and metabolites are closely correlated. These correlations were explored using Spearman’s correlation analysis and screened using volcano plots (Supplementary Figure S7). The result showed that Candidatus_Saccharimonas, Romboutsia, Clostridium_sensu_stricto_1, and Monoglobus were positively correlated with pregnenolone, pregnenolone sulfate, 19-hydroxyandrost-4-ene-3,17-dione, and glycerophosphocholine and negatively correlated with GlcCer (d18:1/16:0).

3.9. Correlations Network among Gut Microbiota, Differential Metabolites in Feces, Glycolipid Metabolism Parameters in Serum, and Inflammatory Factor in Mice

There were multiple correlations among the serum indices, gut microbiota, and metabolites (Figure 11). All serum glycolipid metabolism indices (TC, TG, FBG, and FINS) were strongly negatively correlated with SCFAs (jasmonic acid, 2-hydroxybutyric acid, succinic acid, L-(+)-lactic acid, and methylmalonic acid), and the SCFAs in feces (AA and BA) were also significantly negatively correlated with these glycolipid metabolic indices (p < 0.05). This further confirmed that hyperlipidemia and hyperglycemia could decrease SCFA production, which could be reversed by PC supplementation. Prasteron-sulfate, GlcCer (d18:1/16:0), 9-hydroxylinoleic_acid, 13(S)-HpoDE, 9(S)-HpODE, and 9,10-DiHOME, belonging to glycolipid metabolites, were strongly negatively correlated with glycolipid metabolism indices and immune factors in serum (TC, TG, FBG, and FINS). Among them, GlcCer (d18:1/16:0) was strongly negatively correlated with Candidatus_Saccharimonas, Clostridium_sensu_stricto_1, and Monoglobus, which were positively correlated with parameters of glycolipid metabolic indices in serum. These results indicated that the HFHF-induced disturbance of serum glucose and lipid metabolism is closely related to gut microbiota and metabolites.

4. Discussion

Although it has been reported that PC has the functions of lowering blood pressure as well as anti-inflammatory, anti-tumor, and hypoglycemic activities [28], the effects of PC as a dietary supplement on gut microbiota, inflammation, and NAFLD have not been investigated. The present study showed that PC was protective against HFHF-induced glucose and lipid metabolism disorder, and its effect was associated with regulating the expression levels of liver glucolipid metabolism genes, systemic inflammation, gut microbiota, and fecal metabolites.
Hyperlipidemia is the most common risk factor for cardiovascular and cerebrovascular diseases and is closely related to the intake of a high-fat diet [37]. Animal experiments showed that the intake of a high-fat diet could significantly increase the levels of plasma TC, TG, and LDL-C and significantly reduce that of HDL-C in rats [38,39]. The current study found that PC significantly decreased fat accumulation and hyperlipidemia in HFHF-fed mice. This may be because PC contains flavonoids and polyphenols. Studies have shown that supplement dietary flavonoids and polyphenols can alleviate HFD-induced obesity, thereby reducing the atherosclerosis index [40,41]. A long-term HFHF diet can further cause liver damage and lipid deposition in the body, thereby causing an irreversible cycle in the body. Moreover, abnormal liver lipid metabolism is related to insulin resistance. Multiple studies have shown that excessive sugar intake leads to impaired glucose tolerance and insulin resistance [42,43]; this was consistent with the results of the current study. Wu et al. showed that the PC water extract could improve the tolerance of mice to sucrose and glucose [44]. The current study also confirmed that PC supplementation significantly inhibited the symptoms of impaired glucose tolerance and insulin resistance in HFHF-fed mice. Therefore, this study confirmed that PC had a preventive and therapeutic effect on the disorder of glucose and lipid metabolism.
De novo lipid (DNL) synthesis refers to the conversion of dietary glucose into fatty acids, which further synthesize TG [45]. The liver and adipose tissues are the main organs responsible for DNL synthesis [46]. Due to a series of enzymatic reactions and cytokines involved in regulating lipid anabolic metabolism, liver DNL synthesis is more efficient than that on adipose tissue. Moreover, some anti-obesity and hypoglycemic drug candidates could prevent lipid and blood glucose levels by regulating liver glucose and lipid metabolism. Fatty acid synthase (FAS), acetyl-coA carboxylase 1 (ACC1), and stearoyl CoA desaturase (SCD) are the key enzymes in natural fatty acid synthesis [47]. A high-fat diet could significantly upregulate the transcription levels of FAS and ACC1 in the liver and increase the lipid synthesis load in the liver as well as significantly increase the levels of TG and LDL-C [31,48]. The current study showed that high-dose PC supplementation could significantly downregulate the expression levels of FAS, ACC1, and SCD1 in the liver. As compared to the HFHF model group, the PC supplementation also significantly downregulated the expression levels of the SREBP-1c gene. SREBP-1c mainly regulates genes related to triglyceride and fatty acid synthesis, such as ACC and SCD1 [49]. Recent studies have shown that SREBP-1c can also inhibit the transcription of insulin receptor substrate-2 (IRS-2), thereby exacerbating insulin resistance; this suggested that it might have a negative regulatory effect on insulin signaling [50,51]. ChREBPα is a transcription factor in the glucose signaling pathway, which plays an important role in regulating glucose metabolism [52], fat metabolism, and fat deposition in mammals [53]. It acts synergistically with SREBP-1c to regulate the expression of glycolysis and fatty acid synthetase genes. In this study, the PC supplementation significantly reduced the ChREBPα gene expression, inhibited lipid synthesis, and regulated abnormal glucose metabolism.
Fatty acid oxidation metabolism in the liver is another important pathway affecting the formation of a fatty liver. PPARα plays a key role in regulating lipid metabolism, glucose homeostasis, and the anti-inflammatory response, and the upregulation of PPARα expression at the mRNA level could increase fatty acid catabolism and decrease fat mass, thus decreasing TG and LDL-C levels in the liver [32,54]. Cpt1α was the target gene of the PPARα-mediated fatty acid oxidation pathway, and the Acox1 gene is a key enzyme in the peroxisome oxidation pathway. A high-fat diet can reduce the expressions of PPARα, Cpt1α, and Acox1 genes in the liver of model group mice, indicating that the lipid oxidative metabolism pathway of non-alcoholic fatty liver mice was blocked by a high-fat diet [55]. PC supplementation improves the expression of those three genes. The above research indicated that PC could inhibit the occurrence of lipid metabolism disorder and adipose tissue deposition in HFHF mice by regulating gene expression involved in lipid synthesis and oxidation metabolism.
To verify the effects of PC on glucose homeostasis in HFHF-fed mice and reveal the mechanism of PC on improving insulin resistance, the expression levels of two gluconeogen-related genes, phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase), in mice liver were determined in this study. The deficiency of these major enzymes in T2DM resulted in the dysregulation of glucose homeostasis [56]. The current results indicated that the mRNA expression levels of G6Pase and PEPCK in mice liver were significantly downregulated in the PC treatment, which might play an important role in inhibiting liver gluconeogenesis.
Chronic low-grade inflammation is an important characteristic of high-fat-diet-induced obesity [57]. Inflammatory cytokines are also the key factors of insulin resistance. Studies showed that obesity-induced proinflammatory cytokines were closely related to insulin resistance [58,59]. However, in insulin-resistant individuals, a large number of proinflammatory cytokines and inflammatory mediators, especially TNF-α, MCP-1, and IL-6, were upregulated [60]. The current research illustrated for the first time that PC could significantly inhibit HFHF-induced inflammatory response, which was manifested in the reduction of inflammatory factors (TNF-α, IL-1β, and MCP-1) in serum and liver tissues.
However, when gut microbiota is disturbed, the abundance of harmful microorganisms increases, disrupting the intestinal barrier function, increasing plasma endotoxin levels, and exacerbating systemic inflammation in the host. The gut microbiota disturbance is closely related to the occurrence and development of NAFLD, insulin resistance, and inflammation [61]. In contrast, SCFAs are important metabolites, which play an important role in regulating host metabolism. Emerging evidence has shown that gut microbiota compositional alteration and short-chain fatty acids (SCFAs) reduction were observed both in fructose-fed mice [62] and high-fat-fed mice [63]. The PC supplementation partially restored the HFHF-induced decrease in SCFAs, such as butyrate and acetate contents. Butyrate can especially significantly relieve steatohepatitis by regulating the gut microbiota and intestinal barrier function, thereby reducing inflammation and oxidative damage in the liver, and it also has a good effect on blood glucose and energy balance [64].
The addition of PC not only ameliorates the high-fat-diet-induced disorder of glucolipid lipid metabolism but also plays a certain role in regulating the structure and function of gut microbiota. The PC supplementation restored microbial diversity, which was reduced by the HFHF diet. Numerous studies have confirmed that the abundance of Firmicutes increases, while that of Bacteroides decreases in obese individuals [63,65], suggesting that the gut microbiota of these two phyla play an important role in developing obesity. The gut microbiota of HFHF-fed mice was characterized by a lower abundance of Bacteroidetes and an increased abundance of Firmicutes and F/B ratios. PC extract was rich in polysaccharides. Wu et al. also showed that polysaccharides from P. alkekengi could reverse the Bacteroidetes/Firmicutes ratio and reduce lipopolysaccharide generation and inflammation-related bacteria in insulin-resistant mice [66]. These results suggested that PC supplementation could reduce HFHF-induced gut ecological disorder and further improve liver fat accumulation.
Previous studies have demonstrated a causal relationship between gut microbiota regulation and glycolipid metabolism homeostasis. Our study found that PC supplementation could significantly reduce the relative abundance of harmful gut microbiota. Romboutsia, Clostridium_sensu_stricto_1, and Candidatus_Saccharimonas are generally perceived as pathogenic bacteria and interpreted as indicators of less healthy gut microbiota; moreover, they are correlated with obesity, inflammation, dyslipidemia, and necrotic enteritis [32,67,68]. The Spearman’s correlation analysis also showed that Romboutsia, Clostridium_sensu_stricto_1, and Candidatus_Saccharimonas were positively correlated with glucolipid metabolism and inflammatory factors in this study, and the PC supplementation significantly restored the relative abundances of those microbes. Wang et al. [69]. reported that the abundance of Monoglobus increased with disease activity in rheumatoid arthritis (RA) and was positively correlated with the IL-10, TNF-α, and IFN-γ levels. The current study demonstrated that the relative abundance of Monoglobus significantly decreased in PC treatment and was positively correlated with the level of proinflammatory factors. A previous study showed that Monoglobus might have a protective effect on chronic kidney disease [70]. Therefore, the specific effects of Monoglobus on the host under the disease state requires further clarification. In addition, the PC supplementation also significantly increased the abundance of Lactobacillus. According to previous studies, a high-fat diet could significantly decrease the abundance of Lactobacillus, which was closely related to the level of lipid metabolism. The correlation analysis of gut microbiota and related physiological and biochemical indicators in this study indicated that the relative abundance of Lactobacillus was negatively correlated to related lipid metabolic disorder indicators, and it also inhibits chronic inflammation and the exacerbation of hyperglycemia. To a certain extent, these results indicated that PC could improve the richness of probiotics in the gut microbiota of obese mice.
The alteration of gut microbiota composition is always accompanied by significant functional alteration and unavoidably leads to alteration in the metabolites in the gut. Fecal metabolites are the key linkage between gut microbiota and host health. In order to explore the important metabolites involved in the beneficial effects of PC extract, the changes in metabolite profile and metabolic pathways were analyzed using fecal samples. The PLS-DA analysis and volcano plot suggested that the PC supplementation could regulate the metabolic profiles of the mice. Using KEGG enrichment analysis, it was found that the metabolic pathways with the highest enrichment in PC groups were mainly involved in lipid metabolism (linoleic acid metabolism, alpha-linolenic acid metabolism, sphingolipid metabolism, glycerophospholipid metabolism, and steroid hormone biosynthesis) and amino acid metabolism pathways (histidine metabolism and tryptophan metabolism). Studies have shown that histidine can promote lipid reduction, increase insulin sensitivity, and reduce the levels of systemic inflammatory markers in plasma [71], while tryptophan can protect mammalian cells against oxidative stress agents. Sphingolipid plays an important biological role; its metabolism was affected by a high-fat diet, and the gut microbiota can produce sphingolipids to improve resistance to stress [72].
The PC treatment could also regulate glycerophospholipid metabolism and steroid hormone biosynthesis. Glycerophospholipids are the main components of biological membranes and have significant implications for cellular functions; moreover, they are also closely related to the immune system [73]. As a precursor of highly unsaturated fatty acids (HUFAS), alpha-linolenic acid is an essential polyunsaturated fatty acid having various biological functions. The signaling molecules generated after the metabolism of alpha-linolenic acid can regulate the growth of cells. However, the lack of alpha-linolenic acid in the body leads to a disorder of lipid metabolism, a decline in immunity, atherosclerosis, and other diseases [74]. Linoleic acid can also be substituted by intestinal microbiota into co-yoked linoleic acid, which plays a role in improving glycolipid metabolism [75]. Studies have shown that obesity can lead to decreased levels of linoleic and linolenic acid, and a high-fat diet can cause oxidative stress in the gut, leading to over-oxygenation of these two fatty acids [76]. In this study, the contents of α-linolenic acid and linoleic acid in fecal metabolites were regulated after PC intervention, which might have importance for better understanding the potential mechanism of PC intervention in the disorder of glycolipid metabolism.
Recently, metabolomic changes in fecal samples are related to the gut microbiota [77], especially in the occurrence and development of diseases, such as obesity, diabetes, anxiety, etc. Although this study could not determine the causal correlation between gut microbiota and metabolites, the correlation analysis suggested a certain correlation between them. At the same time, we found that serum blood indices were also correlated with fecal metabolites. These results indicated that there was an interaction among “serum indices-gut microbiota-fecal metabolites”. In order to clarify the correlation between the three, future studies should consider fecal microbiota transplantation, inoculation tests of related strains, and the upregulation and downregulation of key metabolites.

5. Conclusions

In conclusion, this study concluded that the dietary supplementation of PC could improve the altered host metabolic homeostasis and play a role in beneficial activities against systemic inflammation. The PC treatment not only significantly altered the composition of gut microbiota but also the fecal metabolites. In subsequent studies, regulating the gut microbiota and their related metabolites can be used as a new entry point to study the mechanism of PC. As a medicine and food item, PC has great potential in the treatment and prevention of glucose and lipid metabolism disorders and their complications.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/nu15112507/s1, Table S1. Sequences of primers used for qPCR in this study. Figure S1. The number of metabolites was annotated and classified based on the HMDB of PC extract. Figure S2. Bacterial taxonomic profiling in the family level of gut microbiota at individual level, and (E–H) significant changes (p < 0.05) in the composition of the gut microbiota at family taxa level. Data are expressed as mean ± SD. Bars marked with different superscript letters (a–c) indicate significant differences at p < 0.05. Figure S3. Multivariate statistical analysis of fecal metabolites measured by untargeted metabolomics analysis in (A) positive and (B) negative ion modes. Figure S4. Expression of differential metabolites in the PCL and HFHF groups was represented by volcano plot (A) in positive and (B) negative ion modes. Figure S5. (A) The number of differential metabolites was annotated and classified based on the HMDB changed by PCL, and (B–D) the differential metabolites were annotated and classified at subclasses in NC, PCH, and PCL group compared with the HFHF group. Figure S6. The enrichment pathway of fecal differential metabolites by Kyoto encyclopedia of genes and genomes (KEGG) analysis. Figure S7. Two-factor correlation network analysis showing correlations among significant differences in specific gut microbiota and co-regulated metabolites in feces.

Author Contributions

Conceptualization, L.L., X.S. and C.Z.; data curation, L.L. and X.W.; formal analysis, N.Y.; funding acquisition, X.W.; investigation, C.Z.; methodology, X.W.; project administration, C.Z.; software, Y.Z.; supervision, C.Z.; validation, L.L., X.S. and C.Z.; visualization, H.G.; writing—original draft, L.L.; writing—review and editing, L.L. and X.S. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Natural Science Foundation of Heilongjiang Province, grant number LH2020H129; Qiqihar Science and Technology Plan Joint Guidance Project, grant number LSFGG-2022055; Health commission of Heilongjiang Province, grant number 20210101060181; the Qiqihar Medical University, grant number 2021-ZDPY-002; and the Heilongjiang undergraduate Innovation and Entrepreneurship Project, grant number 202111230027.

Institutional Review Board Statement

The animal study protocol was approved by the Ethics Committee of the Laboratory Animal Center, Qiqihar Medical University, Qiqihar, China (approval no. QMU-AECC-2021-172).

Informed Consent Statement

Not applicable.

Data Availability Statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Aron-Wisnewsky, J.; Vigliotti, C.; Witjes, J.; Le, P.; Holleboom, A.G.; Verheij, J. Gut microbiota and human NAFLD: Disentangling microbial signatures from metabolic disorders. Nat. Rev. Gastroenterol. Hepatol. 2020, 17, 279–297. [Google Scholar] [CrossRef] [PubMed]
  2. Miah, L.; Strafford, H.; Fonferko-Shadrach, B.; Hollinghurst, J.; Pickrell, W.O.J. Incidence, Prevalence, and Health Care Outcomes in Idiopathic Intracranial Hypertension: A Population Study. Neurology 2021, 96, 1251–1261. [Google Scholar] [CrossRef]
  3. Saltiel, A.R.; Olefsky, J.M. Inflammatory mechanisms linking obesity and metabolic disease. J. Clin. Investig. 2017, 127, 1–4. [Google Scholar] [CrossRef]
  4. Friedman, S.L.; Neuschwander-Tetri, B.A.; Mary, R.; Sanyal, A.J. Mechanisms of NAFLD development and therapeutic strategies. Nat. Med. 2018, 24, 908–922. [Google Scholar] [CrossRef] [PubMed]
  5. Shin, S.S.; Yoon, M. Korean red ginseng (Panax ginseng) inhibits obesity and improves lipid metabolism in high fat diet-fed castrated mice. J. Ethnopharmacol. 2018, 210, 80–87. [Google Scholar] [CrossRef]
  6. Bendor, C.D.; Aya, B.; Orit, P.H.; Arnon, A.; Gilad, T. Cardiovascular morbidity, diabetes and cancer risk among children and adolescents with severe obesity. Cardiovasc. Diabetol. 2020, 19, 79. [Google Scholar] [CrossRef]
  7. de Sousa, A.R.; de Castro Moreira, M.E.; Toledo, R.C.L.; dos Anjos Benjamin, L.; Queiroz, V.A.V.; Veloso, M.P.; de Souza Reis, K.; Martino, H.S.D. Extruded sorghum (Sorghum bicolor L.) reduces metabolic risk of hepatic steatosis in obese rats consuming a high fat diet. Food Res. Int 2018, 112, 48–55. [Google Scholar] [CrossRef]
  8. Yu, K.; Huang, K.; Tang, Z.; Huang, X.; Sun, L.; Pang, L.; Mo, C. Metabolism and antioxidation regulation of total flavanones from Sedum sarmentosum Bunge against high-fat diet-induced fatty liver disease in Nile tilapia (Oreochromis niloticus). J. Fish Physiol. Biochem. 2021, 47, 1149–1164. [Google Scholar] [CrossRef]
  9. Shen, H.; Huang, L.; Dou, H.; Yang, Y.; Wu, H. Effect of Trilobatin from Lithocarpus polystachyus Rehd on Gut Microbiota of Obese Rats Induced by a High-Fat Diet. Nutrients 2021, 13, 891. [Google Scholar] [CrossRef] [PubMed]
  10. Nemati, M.; Zardooz, H.; Rostamkhani, F.; Abadi, A.; Foroughi, F. High-fat diet effects on metabolic responses to chronic stress. Arch. Physiol. Biochem. 2017, 123, 182–191. [Google Scholar] [CrossRef]
  11. Harris, K.F. An introductory review of resistant starch type 2 from high-amylose cereal grains and its effect on glucose and insulin homeostasis. Nutr. Rev. 2019, 77, 748–764. [Google Scholar] [CrossRef]
  12. Liu, B.N.; Liu, X.T.; Liang, Z.H.; Wang, J.H. Gut microbiota in obesity. World J. Gastroenterol. 2021, 27, 3850–3873. [Google Scholar] [CrossRef]
  13. Sang, T.; Guo, C.; Guo, D.; Wu, J.; Wang, Y.; Wang, Y.; Chen, J.; Chen, C.; Wu, K.; Na, K.; et al. Suppression of obesity and inflammation by polysaccharide from sporoderm-broken spore of Ganoderma lucidum via gut microbiota regulation. Carbohydr. Polym. 2021, 256, 117594. [Google Scholar] [CrossRef]
  14. Turnbaugh, P.J.; Hamady, M.; Yatsunenko, T.; Cantarel, B.L.; Duncan, A.; Ley, R.E.; Sogin, M.L.; Jones, W.J.; Roe, B.A.; Affourtit, J. A core gut microbiome in obese and lean twins. Nature 2009, 457, 480. [Google Scholar] [CrossRef] [PubMed]
  15. Fischer, M.M.; Kessler, A.M.; Kieffer, D.A.; Knotts, T.A.; Kim, K.; Wei, A.; Ramsey, J.J.; Fascetti, A.J. Effects of obesity, energy restriction and neutering on the faecal microbiota of cats. Br. J. Nutr. 2017, 7, 513–524. [Google Scholar] [CrossRef]
  16. Bäckhed, F.; Fraser, C.M.; Ringel, Y.; Sanders, M.E.; Sartor, R.B.; Sherman, P.M.; Versalovic, J.; Young, V.; Finlay, B.B. Defining a healthy human gut microbiome: Current concepts, future directions, and clinical applications. Cell Host Microbe 2012, 12, 611–622. [Google Scholar] [CrossRef] [PubMed]
  17. Li, L.; Guo, W.L.; Zhang, W.; Xu, J.; Qian, M.; Bai, W.D.; Zhang, Y.Y.; Rao, P.; Ni, L.; Lv, X.C. Grifola frondosa polysaccharides ameliorate lipid metabolic disorders and gut microbiota dysbiosis in high-fat diet fed rats. Food Funct. 2019, 10, 2560–2572. [Google Scholar] [CrossRef] [PubMed]
  18. Zhi, C.; Huang, J.; Wang, J.; Cao, H.; Bai, Y.; Guo, J.; Su, Z. Connection between gut microbiome and the development of obesity. Eur. J. Clin. Microbiol. 2019, 38, 1919–1987. [Google Scholar] [CrossRef]
  19. Yang, C.; Xu, Z.; Deng, Q.; Huang, Q.; Huang, F. Beneficial effects of flaxseed polysaccharides on metabolic syndrome via gut microbiota in high-fat diet fed mice. Food Res. Int. 2020, 131, 108994. [Google Scholar] [CrossRef]
  20. Feng, L.; Zhou, J.; Zhang, L.; Liu, P.; Wan, X. Gut microbiota-mediated improvement of metabolic disorders by Qingzhuan tea in high fat diet-fed mice. J. Funct. Foods 2021, 78, 104366. [Google Scholar] [CrossRef]
  21. Chen, M.; Liao, Z.; Lu, B.; Wang, M.; Lin, L.; Zhang, S.; Li, Y.; Liu, D.; Liao, Q.; Xie, Z. Huang-Lian-Jie-Du-Decoction Ameliorates Hyperglycemia and Insulin Resistant in Association with Gut Microbiota Modulation. Front. Microbiol. 2018, 9, 2380. [Google Scholar] [CrossRef]
  22. Ding, L.; Ren, S.; Song, Y.; Zang, C.; Liu, Y.; Guo, H.; Yang, W.; Guan, H.; Liu, J. Modulation of gut microbiota and fecal metabolites by corn silk among high-fat diet-induced hypercholesterolemia mice. Front. Nutr. 2022, 9, 935612. [Google Scholar] [CrossRef]
  23. Wenjie, J.L.L.P.T. Bacterial fatty acid biosynt hesisenzy mesdrug targets for anti bacterial agent screen. Period. Dep. Shenyang Pharm. Univ. 2006, 12, 774–775. [Google Scholar]
  24. Hu, H.X.; Xu, L.T.; Gao, H.; Lv, H.; Shen, T. Chemical Constituents from Physalis Calyx seu Fructus and Their Inhibitory Effects against Oxidative Stress and Inflammatory Response. Planta Med. 2020, 86, 1191–1203. [Google Scholar] [CrossRef]
  25. Zhao, X.; Chen, Z.; Yin, Y.; Li, X. Effects of polysaccharide from Physalis alkekengi var. francheti on liver injury and intestinal microflora in type-2 diabetic mice. Pharm. Biol. 2017, 55, 2020–2025. [Google Scholar] [CrossRef] [PubMed]
  26. Chang, Y. The Toxicology of Total Saponins from Physalis alkekengi L. Calyx and the Anti-Hyperlipidemia Activities; Shanxi Agricultural University: Taiyuan, China, 2015. [Google Scholar]
  27. Guo, Y.; Li, S.; Li, J.; Ren, Z.; Chen, F.; Wang, X. Anti-hyperglycemic activity of polysaccharides from calyx of Physalis alkekengi var. franchetii Makino on alloxan-induced mice. Int. J. Biol. Macromol. 2017, 99, 249–257. [Google Scholar] [CrossRef]
  28. Li, A.L.; Chen, B.J.; Li, G.H.; Zhou, M.X.; Li, Y.R.; Ren, D.M.; Lou, H.X.; Wang, X.N.; Shen, T. Physalis alkekengi L. var. franchetii (Mast.) Makino: An ethnomedical, phytochemical and pharmacological review. J. Ethnopharmacol. 2017, 210, 260–274. [Google Scholar] [CrossRef] [PubMed]
  29. Guo, J.; Li, Y.; Li, S.; Guan, H.; Chen, X. Anti-aging activity of physalis calyx and its mechanism. Food Ferment. Ind. 2021, 47, 140–144. [Google Scholar] [CrossRef]
  30. Shang, Y.; Zhou, H.; Hu, M.; Feng, H. Effect of diet on insulin resistance in polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2020, 105, 425. [Google Scholar] [CrossRef]
  31. Song, H.; Chu, Q.; Xu, D.; Xu, Y.; Zheng, X. Purified Betacyanins from Hylocereus undatus Peel Ameliorate Obesity and Insulin Resistance in High-Fat-Diet-Fed Mice. J. Agric. Food Chem. 2016, 64, 236–244. [Google Scholar] [CrossRef]
  32. Wang, X.L.; Li, L.; Bai, M.J.; Zhao, J.X.; Sun, X.J.; Gao, Y.; Yu, H.T.; Chen, X.; Zhang, C.J. Dietary supplementation with Tolypocladium sinense mycelium prevents dyslipidemia inflammation in high fat diet mice by modulation of gut microbiota in mice. Front. Immunol. 2022, 13, 977528. [Google Scholar] [CrossRef] [PubMed]
  33. Edgar, R.C. UPARSE: Highly accurate OTU sequences from microbial amplicon reads. Nat. Methods 2013, 10, 996–998. [Google Scholar] [CrossRef] [PubMed]
  34. Segata, N.; Izard, J.; Waldron, L.; Gevers, D.; Miropolsky, L.; Garrett, W.S.; Huttenhower, C. Metagenomic biomarker discovery and explanation. Genome Biol. 2011, 12, R60. [Google Scholar] [CrossRef]
  35. Wang, X.; Li, L.; Bian, C.; Bai, M.; Yu, H.; Gao, H.; Zhao, J.; Zhang, C.; Zhao, R. Alterations and correlations of gut microbiota, fecal, and serum metabolome characteristics in a rat model of alcohol use disorder. Front. Microbiol. 2023, 13, 1068825. [Google Scholar] [CrossRef]
  36. Smith, C.A.; Want, E.J.; O’Maille, G.; Abagyan, R.; Siuzdak, G. XCMS: Processing Mass Spectrometry Data for Metabolite Profiling Using Nonlinear Peak Alignment, Matching, and Identification. Anal. Chem. 2006, 78, 779–787. [Google Scholar] [CrossRef]
  37. He, N.; Ye, H. Exercise and Hyperlipidemia. Adv. Exp. Med. Biol. 2020, 1228, 79–90. [Google Scholar] [CrossRef]
  38. Cho, I.J.; Kim, S.E.; Choi, B.R.; Park, H.R.; Park, J.E.; Hong, S.H.; Kwon, Y.S.; Oh, W.S.; Ku, S.K. Lemon Balm and Corn Silk Extracts Mitigate High-Fat Diet-Induced Obesity in Mice. Antioxidants 2021, 10, 2015. [Google Scholar] [CrossRef]
  39. Zhu, Z.; Huang, R.; Liu, W.; Wang, J.; Wu, S.; Chen, M.; Xie, Y.; Chen, M.; Jiao, C.; Zhang, J. Front Cover: Whole Agrocybe cylindracea Prevented Obesity Linking with Modification of Gut Microbiota and Associated Fecal Metabolites in High-Fat Diet-Fed Mice. Mol. Nutr. Food Res. 2022, 66, 2270028. [Google Scholar] [CrossRef] [PubMed]
  40. Liu, J.; He, Z.; Ma, N.; Chen, Z.Y. Beneficial Effects of Dietary Polyphenols on High-Fat Diet-Induced Obesity Linking with Modulation of Gut Microbiota. J. Agric. Food Chem. 2020, 68, 33–47. [Google Scholar] [CrossRef]
  41. Hao, Y.; Zhou, F.; Dong, J.; Wang, Y.; Lang, Z.; Li, S.; Li, S. Study on the role of flavonoids derived extract from seed residues of hippophae rhamnoides on high-fat diet induced obese mice. J. King Saud Univ. Sci. 2020, 32, 1597–1603. [Google Scholar] [CrossRef]
  42. Ya, A.; Hy, B.; Em, C.; My, D.; Ik, E.; At, F.; Yn, E.; Rf, E.; Gme, F.; Ns, A. Maternal High-Fructose Corn Syrup consumption causes insulin resistance and hyperlipidemia in offspring via DNA methylation of the Pparα promoter region. J. Nutr. Biochem. 2022, 103, 108951. [Google Scholar] [CrossRef]
  43. Ahmed, H.M.S.; Mohamed, S.G.; Ibrahim, W.S.; Rezk, A.M.; Mahmoud, A.A.A.; Mahmoud, M.F.; Ibrahim, I. Acute and chronic metabolic effects of carvedilol in high-fructose, high-fat diet-fed mice: Implication of beta-arrestin2 pathway. Can. J. Physiol. Pharmacol. 2022, 100, 68–77. [Google Scholar] [CrossRef] [PubMed]
  44. Wu Hongjie, C.D. Effects of different extracts of Physalis alkekengi L. var. franchetii (Mast.) Makino on blood glucose tolerance in mice and blood glucose level in diabetic nephropathy rats. Anhui Med. Pharm. J. 2018, 22, 1245–1247. [Google Scholar]
  45. Postic, C.; Girard, J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: Lessons from genetically engineered mice. J. Clin. Investig. 2008, 118, 829–838. [Google Scholar] [CrossRef]
  46. Song, Z.Y.; Xiaoli, A.M.; Yang, F.J. Regulation and Metabolic Significance of De Novo Lipogenesis in Adipose Tissues. Nutrients 2018, 10, 1383. [Google Scholar] [CrossRef]
  47. Bódis, K.; Kahl, S.; Simon, M.-C.; Zhou, Z.; Sell, H.; Knebel, B.; Tura, A.; Strassburger, K.; Burkart, V.; Müssig, K.; et al. Reduced expression of stearoyl-CoA desaturase-1, but not free fatty acid receptor 2 or 4 in subcutaneous adipose tissue of patients with newly diagnosed type 2 diabetes mellitus. Nutr. Diabetes 2018, 8, 49. [Google Scholar] [CrossRef]
  48. Won, S.M.; Seo, M.J.; Kwon, M.J.; Park, K.W.; Yoon, J.H. Oral Administration of Latilactobacillus sakei ADM14 Improves Lipid Metabolism and Fecal Microbiota Profile Associated with Metabolic Dysfunction in a High-Fat Diet Mouse Model. Front. Microbiol. 2021, 12, 746601. [Google Scholar] [CrossRef] [PubMed]
  49. Rong, S.X.; Cortes, V.A.; Rashid, S.; Anderson, N.N.; McDonald, J.G.; Liang, G.S.; Moon, Y.A.; Hammer, R.E.; Horton, J.D. Expression of SREBP-lc Requires SREBP2-mediated Generation of a Sterol Ligand for LXR in Livers of Mice. eLife 2017, 6, e25015. [Google Scholar] [CrossRef]
  50. Gong, Z.Q.; Han, S.; Li, C.L.; Meng, T.X.; Huo, Y.; Liu, X.F.; Huang, Y.H.; Yang, L.F. Rhinacanthin C Ameliorates Insulin Resistance and Lipid Accumulation in NAFLD Mice via the AMPK/SIRT1 and SREBP-1c/FAS/ACC Signaling Pathways. Evid. Based Complement. Altern. Med. 2023, 2023, 6603522. [Google Scholar] [CrossRef]
  51. Ortega-Prieto, P.; Postic, C. Carbohydrate Sensing Through the Transcription Factor ChREBP. Front. Genet. 2019, 10, 472. [Google Scholar] [CrossRef]
  52. Herman, M.A.; Peroni, O.D.; Villoria, J.; Schon, M.R.; Abumrad, N.A.; Bluher, M.; Klein, S.; Kahn, B.B. A novel ChREBP isoform in adipose tissue regulates systemic glucose metabolism. Nature 2012, 484, 333–338. [Google Scholar] [CrossRef] [PubMed]
  53. Ke, H.Y.; Luan, Y.; Wu, S.M.; Zhu, Y.M.; Tong, X.M. The Role of Mondo Family Transcription Factors in Nutrient-Sensing and Obesity. Front. Endocrinol. 2021, 12, 653972. [Google Scholar] [CrossRef] [PubMed]
  54. Jie, X.U.; Yan, T.; Zhang, K.; Gao, Y.; Liu, H. Protective Effects of Yinzhihuang Combined with Metformin on Nonalcoholic Fatty Liver Diseases Based on PPAR-α Signaling Pathway. Med. Plant 2020, 11, 66–69. [Google Scholar] [CrossRef]
  55. Ham, J.R.; Lee, M.J.; Lee, H.-I.; Lee, H.-J.; Kim, H.Y.; Seo, W.-D.; Son, Y.-J.; Mi-Kyung, L. Anti-Diabetic Activity of Heuksoojeongchal Bran Prethanol Extract in HFD/STZ-Induced Diabetic Mice. J. Korean Soc. Food Sci. Nutr. 2021, 50, 655–663. [Google Scholar] [CrossRef]
  56. Zhu, Y.X.; Hu, H.Q.; Zuo, M.L.; Mao, L.; Song, G.L.; Li, T.M.; Dong, L.C.; Yang, Z.B.; Sheikh, M.S.A. Effect of oxymatrine on liver gluconeogenesis is associated with the regulation of PEPCK and G6Pase expression and AKT phosphorylation. Biomed. Rep. 2021, 15, 56. [Google Scholar] [CrossRef] [PubMed]
  57. Luo, Y.F.; Lin, H. Inflammation initiates a vicious cycle between obesity and nonalcoholic fatty liver disease. Immun. Inflamm. Dis. 2021, 9, 59–73. [Google Scholar] [CrossRef]
  58. Li, H.; Meng, Y.; He, S.W.; Tan, X.C.; Zhang, Y.J.; Zhang, X.L.; Wang, L.L.; Zheng, W.S. Macrophages, Chronic Inflammation, and Insulin Resistance. Cells 2022, 11, 3001. [Google Scholar] [CrossRef]
  59. Xu, L.; Yan, X.Y.; Zhao, Y.X.; Wang, J.; Liu, B.H.; Yu, S.H.; Fu, J.Y.; Liu, Y.N.; Su, J. Macrophage Polarization Mediated by Mitochondrial Dysfunction Induces Adipose Tissue Inflammation in Obesity. Int. J. Mol. Sci. 2022, 23, 9252. [Google Scholar] [CrossRef]
  60. Yin, H.W.; Yang, X.J.; Liu, S.B.; Zeng, J.; Chen, S.H.; Zhang, S.L.; Liu, Y.; Zhao, Y.T. Total flavonoids from Lagerstroemia speciosa (L.) Pers inhibits TNF-alpha-induced insulin resistance and inflammatory response in 3T3-L1 adipocytes via MAPK and NF-kappa B signaling pathways. Food Sci. Technol. 2022, 42, e45222. [Google Scholar] [CrossRef]
  61. Chen, L.L.; Kan, J.T.; Zheng, N.N.; Li, B.B.; Hong, Y.; Yan, J.; Tao, X.; Wu, G.S.; Ma, J.L.; Zhu, W.Z.; et al. A botanical dietary supplement from white peony and licorice attenuates nonalcoholic fatty liver disease by modulating gut microbiota and reducing inflammation. Phytomedicine 2021, 91, 153693. [Google Scholar] [CrossRef]
  62. Li, J.M.; Yu, R.; Zhang, L.P.; Wen, S.Y.; Wang, S.J.; Zhang, X.Y.; Xu, Q.; Kong, L.D. Dietary fructose-induced gut dysbiosis promotes mouse hippocampal neuroinflammation: A benefit of short-chain fatty acids. Microbiome 2019, 7, 98. [Google Scholar] [CrossRef] [PubMed]
  63. Yang, M.; Yin, Y.X.; Wang, F.; Zhang, H.H.; Ma, X.K.; Yin, Y.L.; Tan, B.; Chen, J.S. Supplementation with Lycium barbarum Polysaccharides Reduce Obesity in High-Fat Diet-Fed Mice by Modulation of Gut Microbiota. Front. Microbiol. 2021, 12, 719967. [Google Scholar] [CrossRef]
  64. Amiri, P.; Arefhosseini, S.; Bakhshimoghaddam, F.; Gurvan, H.; Hosseini, S.A. Mechanistic insights into the pleiotropic effects of butyrate as a potential therapeutic agent on NAFLD management: A systematic review. Front. Nutr. 2022, 9, 1037696. [Google Scholar] [CrossRef]
  65. Chen, Y.F.; Jin, L.; Li, Y.H.; Xia, G.B.; Chen, C.; Zhang, Y. Bamboo-shaving polysaccharide protects against high-diet induced obesity and modulates the gut microbiota of mice. J. Funct. Foods 2018, 49, 20–31. [Google Scholar] [CrossRef]
  66. Wu, Y.; Dong, L.; Song, Y.; Wu, Y.; Zhang, Y.; Wang, S. Preventive effects of polysaccharides from Physalis alkekengi L. on dietary advanced glycation end product-induced insulin resistance in mice associated with the modulation of gut microbiota. Int. J. Biol. Macromol. 2022, 204, 204–214. [Google Scholar] [CrossRef] [PubMed]
  67. Zhai, Z.Y.; Zhang, F.; Cao, R.H.; Ni, X.J.; Xin, Z.Q.; Deng, J.P.; Wu, G.Y.; Ren, W.K.; Yin, Y.L.; Deng, B.C. Cecropin A Alleviates Inflammation Through Modulating the Gut Microbiota of C57BL/6 Mice with DSS-Induced IBD. Front. Microbiol. 2019, 10, 1595. [Google Scholar] [CrossRef]
  68. Shi, N.; Zhang, S.; Silverman, G.; Li, M.; Cai, J.; Niu, H. Protective effect of hydroxychloroquine on rheumatoid arthritis-associated atherosclerosis. Anim. Model. Exp. Med. 2019, 2, 98–106. [Google Scholar] [CrossRef]
  69. Wang, Q.; Zhang, S.X.; Chang, M.J.; Qiao, J.; Wang, C.H.; Li, X.F.; Yu, Q.; He, P.F. Characteristics of the Gut Microbiome and Its Relationship with Peripheral CD4(+) T Cell Subpopulations and Cytokines in Rheumatoid Arthritis. Front. Microbiol. 2022, 13, 799602. [Google Scholar] [CrossRef]
  70. Tain, Y.-L.; Chang, C.-I.; Hou, C.-Y.; Chang-Chien, G.-P.; Lin, S.; Hsu, C.-N. Dietary Resveratrol Butyrate Monoester Supplement Improves Hypertension and Kidney Dysfunction in a Young Rat Chronic Kidney Disease Model. Nutrients 2023, 15, 635. [Google Scholar] [CrossRef] [PubMed]
  71. DiNicolantonio, J.J.; McCarty, M.F.; Okeefe, J.H. Role of dietary histidine in the prevention of obesity and metabolic syndrome. Open Heart 2018, 5, e000676. [Google Scholar] [CrossRef] [PubMed]
  72. An, D.; Na, C.; Bielawski, J.; Hannun, Y.A.; Kasper, D.L. Membrane sphingolipids as essential molecular signals for Bacteroides survival in the intestine. Proc. Natl. Acad. Sci. USA 2011, 108, 4666–4671. [Google Scholar] [CrossRef] [PubMed]
  73. Snider, S.A.; Margison, K.D.; Ghorbani, P.; LeBlond, N.D.; O’Dwyer, C.; Nunes, J.R.C.; Thao, N.; Xu, H.; Bennett, S.A.L.; Fullerton, M.D. Choline transport links macrophage phospholipid metabolism and inflammation. J. Biol. Chem. 2018, 293, 11600–11611. [Google Scholar] [CrossRef]
  74. Singer, P.; Jaeger, W.; Berger, I.; Barleben, H.; Wirth, M.; Richter-Heinrich, E.; Voigt, S.; Godicke, W. Effects of dietary oleic, linoleic and alpha-linolenic acids on blood pressure, serum lipids, lipoproteins and the formation of eicosanoid precursors in patients with mild essential hypertension. J. Hum. Hypertens. 1990, 4, 227–233. [Google Scholar]
  75. Xia, J.; Zheng, M.; Li, L.; Hou, X.; Zeng, W. Conjugated linoleic acid improves glucose and lipid metabolism in diabetic mice. J. S. Med. Univ. 2019, 39, 740–746. [Google Scholar] [CrossRef]
  76. Xu, Q.; Liu, Y.; Zhang, Q.; Ma, B.; Yang, Z.; Liu, L.; Yao, D.; Cui, G.; Sun, J.; Wu, Z. Metabolomic analysis of simvastatin and fenofibrate intervention in high-lipid diet-induced hyperlipidemia rats. Acta Pharmacol. Sin. 2014, 35, 1265–1273. [Google Scholar] [CrossRef] [PubMed]
  77. Cunningham, A.L.; Stephens, J.W.; Harris, D.A. Intestinal microbiota and their metabolic contribution to type 2 diabetes and obesity. J. Diabetes Metab. Disord. 2021, 20, 1855–1870. [Google Scholar] [CrossRef]
Nutrients 15 02507 g002 550
Figure 2. Effects of PC intervention on glucose homeostasis and alleviated insulin resistance in mice. (A) The oral glucose tolerance test (OGTT) curve in mice. *** represents p < 0.001 when NC group is compared with HFHF group; † represents p < 0.05 and ††† represents p < 0.001 when PCL group is compared with HFHF group; # represents p < 0.05, ## represents p < 0.01, and ### represents p < 0.001 when PCH group is compared with HFHF group. The area under the curve (AUC) (B). Serum fasting insulin (FINS) levels (C), and Homeostasis model assessment of insulin resistance (HOMA-IR) (D) and insulin sensitive (HOMA-IS) index (E). Data are expressed as means ± SD (n = 7). * represents p < 0.05, ** represents p < 0.01, *** represents p < 0.001.
Figure 2. Effects of PC intervention on glucose homeostasis and alleviated insulin resistance in mice. (A) The oral glucose tolerance test (OGTT) curve in mice. *** represents p < 0.001 when NC group is compared with HFHF group; † represents p < 0.05 and ††† represents p < 0.001 when PCL group is compared with HFHF group; # represents p < 0.05, ## represents p < 0.01, and ### represents p < 0.001 when PCH group is compared with HFHF group. The area under the curve (AUC) (B). Serum fasting insulin (FINS) levels (C), and Homeostasis model assessment of insulin resistance (HOMA-IR) (D) and insulin sensitive (HOMA-IS) index (E). Data are expressed as means ± SD (n = 7). * represents p < 0.05, ** represents p < 0.01, *** represents p < 0.001.
Nutrients 15 02507 g002
Nutrients 15 02507 g003 550
Figure 3. Effects of PC supplementation on the serum and liver (A or F) triglyceride (TG), (B or G) total cholesterol (TC), (C or H) non-esterified fatty acid levels (NEFA), (D) low-density lipoprotein cholesterol (LDL-C) in serum, (E) high-density lipoprotein cholesterol (LDL-C) in serum, (I,J) serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities, and (K) H&E staining of mice livers. The length of the black line in the figure represents 100 μm. Values are expressed as mean ± SD in each group (n = 7). * represents p < 0.05, ** represents p < 0.01, *** represents p < 0.001, and ns represents not significant.
Figure 3. Effects of PC supplementation on the serum and liver (A or F) triglyceride (TG), (B or G) total cholesterol (TC), (C or H) non-esterified fatty acid levels (NEFA), (D) low-density lipoprotein cholesterol (LDL-C) in serum, (E) high-density lipoprotein cholesterol (LDL-C) in serum, (I,J) serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities, and (K) H&E staining of mice livers. The length of the black line in the figure represents 100 μm. Values are expressed as mean ± SD in each group (n = 7). * represents p < 0.05, ** represents p < 0.01, *** represents p < 0.001, and ns represents not significant.
Nutrients 15 02507 g003
Nutrients 15 02507 g004 550
Figure 4. Effects of PC supplementation on the transcription of genes related to glycolipid metabolism in the liver. (A) Lipid synthesis, Fas fatty acid synthase (FAS); Acetyl-CoA Carboxylase 1 (ACC1); stearoyl-CoA desaturase 1(SCD1); sterol regulatory element-binding protein-1C (SREBP-1c); and Carbohydrate-response element-binding proteins (ChREBPα). (B) Fatty acid oxidation, peroxisome proliferator-activated receptor α (Pparα); carnitine palmitoyltransferase 1a (Cpt1a); and acyl-coenzyme A oxidase 1 (Acox1). (C) Gluconeogenesis pathway, Glucose-6-phosphatase (G6Pase); phosphoenolpyruvate carboxykinase (PEPCK). Data are expressed as means ± SD (n = 7). * represents p < 0.05, ** represents p < 0.01, *** represents p < 0.001, and ns represents not significant.
Figure 4. Effects of PC supplementation on the transcription of genes related to glycolipid metabolism in the liver. (A) Lipid synthesis, Fas fatty acid synthase (FAS); Acetyl-CoA Carboxylase 1 (ACC1); stearoyl-CoA desaturase 1(SCD1); sterol regulatory element-binding protein-1C (SREBP-1c); and Carbohydrate-response element-binding proteins (ChREBPα). (B) Fatty acid oxidation, peroxisome proliferator-activated receptor α (Pparα); carnitine palmitoyltransferase 1a (Cpt1a); and acyl-coenzyme A oxidase 1 (Acox1). (C) Gluconeogenesis pathway, Glucose-6-phosphatase (G6Pase); phosphoenolpyruvate carboxykinase (PEPCK). Data are expressed as means ± SD (n = 7). * represents p < 0.05, ** represents p < 0.01, *** represents p < 0.001, and ns represents not significant.
Nutrients 15 02507 g004
Nutrients 15 02507 g005 550
Figure 5. Effect of PC supplementation on inflammation in serum (A,B) and in hepatic (C). Effect of PC on LPS in serum (D). Data are expressed as means ± SD (n = 7), ** represents p < 0.01, *** represents p < 0.001, and ns represents not significant.
Figure 5. Effect of PC supplementation on inflammation in serum (A,B) and in hepatic (C). Effect of PC on LPS in serum (D). Data are expressed as means ± SD (n = 7), ** represents p < 0.01, *** represents p < 0.001, and ns represents not significant.
Nutrients 15 02507 g005
Nutrients 15 02507 g006 550
Figure 6. Effects of PC supplementation on SCFAs production in (A) acetic acid, (B) propionate acid, (C) butyrate acid, (D) isobutyric acid, (E) valerate acid, and (F) total SCFAs of fecal contents. Data are expressed as means ± SD (n = 7), * represents p < 0.05, ** represents p < 0.01, *** represents p < 0.001, and ns represents not significant.
Figure 6. Effects of PC supplementation on SCFAs production in (A) acetic acid, (B) propionate acid, (C) butyrate acid, (D) isobutyric acid, (E) valerate acid, and (F) total SCFAs of fecal contents. Data are expressed as means ± SD (n = 7), * represents p < 0.05, ** represents p < 0.01, *** represents p < 0.001, and ns represents not significant.
Nutrients 15 02507 g006
Nutrients 15 02507 g007 550
Figure 7. Effect of PC supplementation on composition of the gut microbiota. (A) Alpha diversity analysis of Chao1, Shannon, and Simpson index, (B) PCoA plot based on Bray—Curtis distance, (C) non-metric multidimensional scaling (NMDS), (D) bacterial taxonomic profiling in the phylum level, and (E–H) significantly changes (p < 0.05) in the relative abundance of the gut microbiota at phylum taxa level. Data are expressed as mean ± SD, * represents p < 0.05, ** represents p < 0.01, *** represents p < 0.001, and ns represents not significant.
Figure 7. Effect of PC supplementation on composition of the gut microbiota. (A) Alpha diversity analysis of Chao1, Shannon, and Simpson index, (B) PCoA plot based on Bray—Curtis distance, (C) non-metric multidimensional scaling (NMDS), (D) bacterial taxonomic profiling in the phylum level, and (E–H) significantly changes (p < 0.05) in the relative abundance of the gut microbiota at phylum taxa level. Data are expressed as mean ± SD, * represents p < 0.05, ** represents p < 0.01, *** represents p < 0.001, and ns represents not significant.
Nutrients 15 02507 g007
Nutrients 15 02507 g008 550
Figure 8. Deep analysis of gut microbiota at genus level in mice. (A) The top 15 abundances of the gut microbiota at the genus level in heat map, (B) Bacterial genus significantly changed by HFHF, and the treatment of PC among top 15 taxa of the composition of the gut microbiota at genus level. Data are expressed as mean ± SD, * represents p < 0.05, ** represents p < 0.01, *** represents p < 0.001, and ns represents not significant. (C) Linear discriminant analysis effect size (LEfSe) analysis of key genera of gut microbiota in mice and the LDA score > 4.5, and (D) correlation between the gut microbiota and biochemical indexes at the genus level. * p < 0.05, ** p < 0.01. AA, acetic acid; BA, butyrate acid; PA, propionate acid; VA, valerate acid.
Figure 8. Deep analysis of gut microbiota at genus level in mice. (A) The top 15 abundances of the gut microbiota at the genus level in heat map, (B) Bacterial genus significantly changed by HFHF, and the treatment of PC among top 15 taxa of the composition of the gut microbiota at genus level. Data are expressed as mean ± SD, * represents p < 0.05, ** represents p < 0.01, *** represents p < 0.001, and ns represents not significant. (C) Linear discriminant analysis effect size (LEfSe) analysis of key genera of gut microbiota in mice and the LDA score > 4.5, and (D) correlation between the gut microbiota and biochemical indexes at the genus level. * p < 0.05, ** p < 0.01. AA, acetic acid; BA, butyrate acid; PA, propionate acid; VA, valerate acid.
Nutrients 15 02507 g008
Nutrients 15 02507 g009 550
Figure 9. The fecal metabolic profile altered by PC in HFHF–fed mice. (A) Score plot of the PCA model in the positive and negative ion modes. (B) Score plot of the OPLS–DA model in positive and negative ion modes between NC and HFHF. (C) Score plot of the OPLS–DA model in positive and negative ion modes between HFHF and PCH.
Figure 9. The fecal metabolic profile altered by PC in HFHF–fed mice. (A) Score plot of the PCA model in the positive and negative ion modes. (B) Score plot of the OPLS–DA model in positive and negative ion modes between NC and HFHF. (C) Score plot of the OPLS–DA model in positive and negative ion modes between HFHF and PCH.
Nutrients 15 02507 g009
Nutrients 15 02507 g010 550
Figure 10. The fecal metabolites altered in mice. Differential metabolites in fecal identification in different groups in (A,C,E) positive and (B,D,F) negative ion modes, and expression of differential metabolites in the two groups was represented by (A–D) volcano plot and (E,F) heat maps. (G) The number of differential metabolites was annotated and classified based on the HMDB changed by HFHF and the treatment of PCH. (H) The enrichment metabolic pathway of fecal altered metabolites by Kyoto encyclopedia of genes and genomes (KEGG) analysis.
Figure 10. The fecal metabolites altered in mice. Differential metabolites in fecal identification in different groups in (A,C,E) positive and (B,D,F) negative ion modes, and expression of differential metabolites in the two groups was represented by (A–D) volcano plot and (E,F) heat maps. (G) The number of differential metabolites was annotated and classified based on the HMDB changed by HFHF and the treatment of PCH. (H) The enrichment metabolic pathway of fecal altered metabolites by Kyoto encyclopedia of genes and genomes (KEGG) analysis.
Nutrients 15 02507 g010
Nutrients 15 02507 g011 550
Figure 11. Correlation network analysis showing correlations among significant differences in specific gut microbiota, co-regulated metabolites in feces, and obesity-related biomarkers; the red line represents the positive correlation and the blue line represents negative correlation. |r| > 0.8, p < 0.05.
Figure 11. Correlation network analysis showing correlations among significant differences in specific gut microbiota, co-regulated metabolites in feces, and obesity-related biomarkers; the red line represents the positive correlation and the blue line represents negative correlation. |r| > 0.8, p < 0.05.
Nutrients 15 02507 g011
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Li, L.; Wang, X.; Zhou, Y.; Yan, N.; Gao, H.; Sun, X.; Zhang, C. Physalis alkekengi L. Calyx Extract Alleviates Glycolipid Metabolic Disturbance and Inflammation by Modulating Gut Microbiota, Fecal Metabolites, and Glycolipid Metabolism Gene Expression in Obese Mice. Nutrients 2023, 15, 2507. https://doi.org/10.3390/nu15112507

AMA Style

Li L, Wang X, Zhou Y, Yan N, Gao H, Sun X, Zhang C. Physalis alkekengi L. Calyx Extract Alleviates Glycolipid Metabolic Disturbance and Inflammation by Modulating Gut Microbiota, Fecal Metabolites, and Glycolipid Metabolism Gene Expression in Obese Mice. Nutrients. 2023; 15(11):2507. https://doi.org/10.3390/nu15112507

Chicago/Turabian Style

Li, Lin, Xiaolong Wang, Ying Zhou, Na Yan, Han Gao, Xiaojie Sun, and Chunjing Zhang. 2023. "Physalis alkekengi L. Calyx Extract Alleviates Glycolipid Metabolic Disturbance and Inflammation by Modulating Gut Microbiota, Fecal Metabolites, and Glycolipid Metabolism Gene Expression in Obese Mice" Nutrients 15, no. 11: 2507. https://doi.org/10.3390/nu15112507

APA Style

Li, L., Wang, X., Zhou, Y., Yan, N., Gao, H., Sun, X., & Zhang, C. (2023). Physalis alkekengi L. Calyx Extract Alleviates Glycolipid Metabolic Disturbance and Inflammation by Modulating Gut Microbiota, Fecal Metabolites, and Glycolipid Metabolism Gene Expression in Obese Mice. Nutrients, 15(11), 2507. https://doi.org/10.3390/nu15112507

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop